GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A3494 INCB3344Target: CCRSummary: CCR2 chemokine receptor antagonist -
A3495 INCB8761(PF-4136309)Summary: CCR2 Antagonist,potent and selective -
A3496 IndacaterolSummary: β2-agonist -
A3538 LaropiprantSummary: DP1 receptor antagonist,potent and selective -
A3561 Lu AE58054 HydrochlorideSummary: 5-HT(6)R antagonist -
A3563 LUF6000Summary: A3 AR modulator -
A3577 LY341495Summary: Metabotropic glutamate receptor antagonist -
A3587 MBX-2982Summary: GPR119 agonist,selective and orally-available -
A3592 Medetomidine1 CitationSummary: α2-adrenoceptor agonist -
A3601 mGlu2 agonistSummary: Anti-depressants,novel potent agent

